A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.
A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.
复制标题
DOI：
10.1007/s10549-009-0664-y
复制
发表时间：
2010-10
影响因子：
3.8
通讯作者：
Aft, Rebecca L.
中科院分区：
文献类型：
--
作者：
Lin, Yiing;Lin, Shin;Watson, Mark;Trinkaus, Kathryn M.;Kuo, Sacha;Naughton, Michael J.;Weilbaecher, Katherine;Fleming, Timothy P.;Aft, Rebecca L.
已经报道了几种基因表达谱来预测乳腺癌对新辅助化疗的反应。这些研究通常认为乳腺癌是一个同质实体，尽管已知基底细胞样亚类的病理完全缓解（pCR）率较高。我们假设，具有更高预测准确性的配置文件可以从孤立的基底细胞样肿瘤的子集分析中获得。使用先前描述的“内在”特征来区分乳腺肿瘤亚类，我们从两个独立的临床试验中鉴定了50个与基因表达谱数据相关的基底样肿瘤。24个肿瘤数据集来自我们机构的119名患者新辅助试验，另外26个肿瘤数据集来自公开的数据集（Hess等人，J Clin Oncol 24：4236-4244，2006）。将合并的50个基底样肿瘤划分以形成37个样本训练集，其中13个被隔离用于验证。临床监测平均持续26个月。我们确定了一个23个基因的档案，预测pCR在基底样乳腺癌与92%的预测准确率在隔离验证数据集。此外，基于具有23个基因标签的聚类分析，观察到具有高癌症复发率的患者的不同聚类。对这三组患者的无病生存分析显示，高复发组患者的生存率显著降低。我们确定了一个23个基因的签名，预测基底细胞样乳腺癌对新辅助化疗的反应以及无病生存率。该特征与组织收集方法和化疗方案无关。
Several gene expression profiles have been reported to predict breast cancer response to neoadjuvant chemotherapy. These studies often consider breast cancer as a homogeneous entity, although higher rates of pathologic complete response (pCR) are known to occur within the basal-like subclass. We postulated that profiles with higher predictive accuracy could be derived from a subset analysis of basal-like tumors in isolation. Using a previously described “intrinsic” signature to differentiate breast tumor subclasses, we identified 50 basal-like tumors from two independent clinical trials associated with gene expression profile data. 24 tumor data sets were derived from a 119-patient neoadjuvant trial at our institution and an additional 26 tumor data sets were identified from a published data set (Hess et al. J Clin Oncol 24:4236–4244, 2006). The combined 50 basal-like tumors were partitioned to form a 37 sample training set with 13 sequestered for validation. Clinical surveillance occurred for a mean of 26 months. We identified a 23-gene profile which predicted pCR in basal-like breast cancers with 92% predictive accuracy in the sequestered validation data set. Furthermore, distinct cluster of patients with high rates of cancer recurrence was observed based on cluster analysis with the 23-gene signature. Disease-free survival analysis of these three clusters revealed significantly reduced survival in the patients of this high recurrence cluster. We identified a 23-gene signature which predicts response of basal-like breast cancer to neoadjuvant chemotherapy as well as disease-free survival. This signature is independent of tissue collection method and chemotherapeutic regimen.
登录
查看更多内容
影响因子：
11.2
作者：
Bertucci, F;Finetti, P;Viens, P
通讯作者：
Viens, P
DOI：
10.1073/pnas.0932692100
发表时间：
2003-07-08
影响因子：
11.1
作者：
Sorlie, T;Tibshirani, R;Botstein, D
通讯作者：
Botstein, D
影响因子：
45.3
作者：
Hannemann, J;Oosterkamp, HM;van de Vijver, MJ
通讯作者：
van de Vijver, MJ
影响因子：
11.5
作者：
Carey, Lisa A.;Dees, E. Claire;Perou, Charles M.
通讯作者：
Perou, Charles M.
影响因子：
45.3
作者：
Mazouni, Chafika;Peintinger, Florentia;Pusztai, Lajos
通讯作者：
Pusztai, Lajos